Palonosetron
- Generic Name
- Palonosetron
- Brand Names
- Akynzeo, Aloxi, Palonosetron Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O
- CAS Number
- 135729-56-5
- Unique Ingredient Identifier
- 5D06587D6R
- Background
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is...
- Indication
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
- Associated Conditions
- Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
- Associated Therapies
- -
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT01909856
- Locations
- 🇨🇳
Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 196
- Registration Number
- NCT01825733
The Effect of Palonosetron on the QTc Interval During Perioperative Period
- Conditions
- Interventions
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01650961
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2013-12-25
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 384
- Registration Number
- NCT01568268
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Bungdang Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Kangpook Samsung Hospital, Seoul, Korea, Republic of
Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2011-11-22
- Lead Sponsor
- Incheon St.Mary's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01476280
- Locations
- 🇰🇷
Incheon St. Mary's hospital, Incheon, Korea, Republic of
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 502
- Registration Number
- NCT01442376
- Locations
- 🇺🇸
A. I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Nemours Children's Clinic, Pensacola, Florida, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 670
- Registration Number
- NCT01395901
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
🇵🇱Department of Intensive Care and Anesthesiology, Olsztyn, Poland
🇺🇸Shoals Medical Research, LLC, Sheffield, Alabama, United States
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 413
- Registration Number
- NCT01376297
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Veterans Administration New Jersey Health Care System, East Orange, New Jersey, United States
🇺🇸East Valley Hematology and Oncology Medical Group, Burbank, California, United States
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01370408
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 1455
- Registration Number
- NCT01339260
- Locations
- 🇺🇸
Cancer Specialists of South Texas, P.A., Corpus Christi, Texas, United States
🇺🇸The John R Marsh Cancer Center, Hagerstown, Maryland, United States
🇺🇸Compassionate Cancer Centre Medical Group, Fountain Valley, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.